Barriers to Compliance with National Guidelines Among Children Hospitalized with Community-Acquired Pneumonia in Vietnam and the Implications
Abstract
1. Introduction
- Amoxicillin is the first-line antibiotic of choice, with amoxicillin/clavulanic acid, cefuroxime, cefaclor, erythromycin and azithromycin listed as second-line alternatives
- For the treatment of severe pneumonia in children: Penicillin A with an aminoglycoside antibiotic. If initial treatments fail, ceftriaxone or cefotaxime can be administered intravenously.
- Antibiotics are recommended for a minimum period of 5 days, with intravenous antibiotics reserved for children who experience pneumonia-related complications (e.g., empyema) or a poor response to oral antibiotics.
- Intravenous to oral step-down antibiotic is advised following adequate clinical recovery and once oral antibiotics can be tolerated
2. Results
3. Discussion
4. Materials and Methods
4.1. Research Design and Subjects
4.2. Data Collecting and Processing Methods
- Medical records of patients with a confirmed diagnosis of pneumonia (ICD code of discharge diagnosis is J12 to J18);
- Medical records of patients aged 2 months—5 years;
- Medical records of patients with indications for antibiotic use within 48 h of admission;
- Medical records of inpatients for 3 days or more. This date was chosen to ensure that the selected cases were truly cases of CAP and patients had undergone a sufficiently long initial treatment period to allow meaningful analysis, i.e., helping to exclude cases of uncertain diagnosis. This is because we were aware that some children are admitted to hospitals in Vietnam with symptoms resembling pneumonia; however, this may be another infectious disease that quickly resolves. If the child is discharged or stops treatment within 1–2 days, it is likely that the initial diagnosis of pneumonia was incorrect. Consequently, setting a threshold of 3 days helps to eliminate these cases making the study patient group more homogeneous and robust.
- Medical records of young children in which the diagnosis of pneumonia was not recorded within the first 48 h of admission;
- Medical records of patients who were subsequently transferred to another hospital;
- Medical records that could not be accessed.
4.3. Ethical Approval
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Bassat, Q.; Blau, D.M.; Ogbuanu, I.U.; Samura, S.; Kaluma, E.; Bassey, I.A.; Sow, S.; Keita, A.M.; Tapia, M.D.; Mehta, A.; et al. Causes of Death Among Infants and Children in the Child Health and Mortality Prevention Surveillance (CHAMPS) Network. JAMA Netw. Open 2023, 6, e2322494. [Google Scholar] [CrossRef] [PubMed]
- Liu, L.; Oza, S.; Hogan, D.; Chu, Y.; Perin, J.; Zhu, J.; Lawn, J.E.; Cousens, S.; Mathers, C.; Black, R.E. Global, regional, and national causes of under-5 mortality in 2000–15: An updated systematic analysis with implications for the Sustainable Development Goals. Lancet 2016, 388, 3027–3035. [Google Scholar] [CrossRef] [PubMed]
- Marangu, D.; Zar, H.J. Childhood pneumonia in low-and-middle-income countries: An update. Paediatr. Respir. Rev. 2019, 32, 3–9. [Google Scholar] [CrossRef] [PubMed]
- Nascimento-Carvalho, C.M. Community-acquired pneumonia among children: The latest evidence for an updated management. J. Pediatr. 2020, 96 (Suppl. 1), 29–38. [Google Scholar] [CrossRef] [PubMed]
- Tran, X.D.; Hoang, V.-T.; Goumballa, N.; Vu, T.N.; Tran, T.K.; Pham, T.D.; Dao, T.-L.; Nguyen, D.C.; Nguyen, Q.T.; Marty, P.; et al. Viral and bacterial microorganisms in Vietnamese children with severe and non-severe pneumonia. Sci. Rep. 2024, 14, 120. [Google Scholar] [CrossRef] [PubMed]
- Nguyen, T.K.; Tran, T.H.; Roberts, C.L.; Graham, S.M.; Marais, B.J. Child pneumonia—Focus on the Western Pacific Region. Paediatr. Respir. Rev. 2017, 21, 102–110. [Google Scholar] [CrossRef] [PubMed]
- Nathan, A.M.; Teh, C.S.J.; Jabar, K.A.; Teoh, B.T.; Tangaperumal, A.; Westerhout, C.; Zaki, R.; Eg, K.P.; Thavagnanam, S.; de Bruyne, J.A.; et al. Bacterial pneumonia and its associated factors in children from a developing country: A prospective cohort study. PLoS ONE 2020, 15, e0228056. [Google Scholar] [CrossRef] [PubMed]
- Sharland, M.; Zanichelli, V.; Ombajo, L.A.; Bazira, J.; Cappello, B.; Chitatanga, R.; Chuki, P.; Gandra, S.; Getahun, H.; Harbarth, S.; et al. The WHO essential medicines list AWaRe book: From a list to a quality improvement system. Clin. Microbiol. Infect. 2022, 28, 1533–1535. [Google Scholar] [CrossRef] [PubMed]
- Nguyen, T.; Bui, B.; Ngo, Q.; Fitzgerald, D.; Graham, S.; Marais, B. Applying lessons learnt from research of child pneumonia management in Vietnam. Paediatr. Respir. Rev. 2021, 39, 65–70. [Google Scholar] [CrossRef] [PubMed]
- Murray, C.J.; Ikuta, K.S.; Sharara, F.; Swetschinski, L.; Aguilar, G.R.; Gray, A.; Han, C.; Bisignano, C.; Rao, P.; Wool, E.; et al. Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis. Lancet 2022, 399, 629–655. [Google Scholar] [CrossRef] [PubMed]
- Antimicrobial Resistance Collaborators. The burden of bacterial antimicrobial resistance in the WHO African region in 2019: A cross-country systematic analysis. Lancet Glob. Health 2024, 12, e201–e216. [Google Scholar] [CrossRef] [PubMed]
- Lewnard, J.A.; Charani, E.; Gleason, A.; Hsu, L.Y.; Khan, W.A.; Karkey, A.; Chandler, C.I.R.; Mashe, T.; Khan, E.M.; Bulabula, A.N.H.; et al. Burden of bacterial antimicrobial resistance in low-income and middle-income countries avertible by existing interventions: An evidence review and modelling analysis. Lancet 2024, 403, 2439–2454. [Google Scholar] [CrossRef] [PubMed]
- Godman, B.; Egwuenu, A.; Haque, M.; Malande, O.O.; Schellack, N.; Kumar, S.; Saleem, Z.; Sneddon, J.; Hoxha, I.; Islam, S.; et al. Strategies to Improve Antimicrobial Utilization with a Special Focus on Developing Countries. Life 2021, 11, 528. [Google Scholar] [CrossRef] [PubMed]
- WHO. Global Action Plan on Antimicrobial Resistance. 2016. Available online: https://www.who.int/publications/i/item/9789241509763 (accessed on 3 May 2025).
- Willemsen, A.; Reid, S.; Assefa, Y. A review of national action plans on antimicrobial resistance: Strengths and weaknesses. Antimicrob. Resist. Infect. Control 2022, 11, 9. [Google Scholar] [CrossRef] [PubMed]
- Torumkuney, D.; Kundu, S.; Van Vu, G.; Nguyen, H.A.; Van Pham, H.; Kamble, P.; Lan, N.T.H.; Keles, N. Country data on AMR in Vietnam in the context of community-acquired respiratory tract infections: Links between antibiotic susceptibility, local and international antibiotic prescribing guidelines, access to medicines and clinical outcome. J. Antimicrob. Chemother. 2022, 77 (Suppl. 1), i26–i34. [Google Scholar] [CrossRef] [PubMed]
- Ministry of Health Vietnam. Vietnam: National Action Plan for Combating Drug Resistance. 2013–2020. 2013. Available online: https://www.who.int/publications/m/item/vietnam-national-action-plan-for-combating-drug-resistance (accessed on 20 April 2025).
- Sharland, M.; Pulcini, C.; Harbarth, S.; Zeng, M.; Gandra, S.; Mathur, S.; Magrini, N. Classifying antibiotics in the WHO Essential Medicines List for optimal use—Be AWaRe. Lancet Infect. Dis. 2018, 18, 18–20. [Google Scholar] [CrossRef] [PubMed]
- Sharland, M.; Gandra, S.; Huttner, B.; Moja, L.; Pulcini, C.; Zeng, M.; Mendelson, M.; Cappello, B.; Cooke, G.; Magrini, N.; et al. Encouraging AWaRe-ness and discouraging inappropriate antibiotic use—The new 2019 Essential Medicines List becomes a global antibiotic stewardship tool. Lancet Infect. Dis. 2019, 19, 1278–1280. [Google Scholar] [CrossRef] [PubMed]
- Moja, L.; Zanichelli, V.; Mertz, D.; Gandra, S.; Cappello, B.; Cooke, G.S.; Chuki, P.; Harbath, S.; Pulcini, C.; Mendelson, M.; et al. WHO’s essential medicines and AWaRe: Recommendations on first- and second-choice antibiotics for empiric treatment of clinical infections. Clin. Microbiol. Infect. 2024, 30, S1–S51. [Google Scholar] [CrossRef] [PubMed]
- Zanichelli, V.; Sharland, M.; Cappello, B.; Moja, L.; Getahun, H.; Pessoa-Silva, C.; Sati, H.; van Weezenbeek, C.; Balkhy, H.; Simão, M.; et al. The WHO AWaRe (Access, Watch, Reserve) antibiotic book and prevention of antimicrobial resistance. Bull. World Health Organ. 2023, 101, 290–296. [Google Scholar] [CrossRef]
- Saleem, Z.; Sheikh, S.; Godman, B.; Haseeb, A.; Afzal, S.; Qamar, M.U.; Imam, M.T.; Abuhussain, S.S.A.; Sharland, M. Increasing the use of the WHO AWaRe system in antibiotic surveillance and stewardship programmes in low- and middle-income countries. JAC-Antimicrob. Resist. 2025, 7, dlaf031. [Google Scholar] [CrossRef] [PubMed]
- Klein, E.Y.; Milkowska-Shibata, M.; Tseng, K.K.; Sharland, M.; Gandra, S.; Pulcini, C.; Laxminarayan, R. Assessment of WHO antibiotic consumption and access targets in 76 countries, 2000–2015: An analysis of pharmaceutical sales data. Lancet Infect. Dis. 2021, 21, 107–115. [Google Scholar] [CrossRef] [PubMed]
- United Nations. Political Declaration of the High-level Meeting on Antimicrobial Resistance. 9 September 2024. Available online: https://www.un.org/pga/wp-content/uploads/sites/108/2024/09/FINAL-Text-AMR-to-PGA.pdf (accessed on 5 May 2025).
- Dat, V.Q. Antibiotic use in public hospitals in Vietnam between 2018 and 2022: A retrospective study. BMJ Open 2024, 14, e087322. [Google Scholar] [CrossRef] [PubMed]
- Nguyen, P.T.; Tran, H.T.; Truong, H.T.; Nguyen, V.T.; Graham, S.M.; Marais, B.J. Paediatric use of antibiotics in children with community acquired pneumonia: A survey from Da Nang, Vietnam. J. Paediatr. Child Health 2019, 55, 1329–1334. [Google Scholar] [CrossRef] [PubMed]
- Nguyen, N.V.; Do, N.T.T.; Vu, D.T.V.; Greer, R.C.; Dittrich, S.; Vandendorpe, M.; Pham, T.N.; Ta, N.T.D.; Pham, T.Q.; Khuong, V.T.; et al. Outpatient antibiotic prescribing for acute respiratory infections in Vietnamese primary care settings by the WHO AWaRe (Access, Watch and Reserve) classification: An analysis using routinely collected electronic prescription data. Lancet Reg. Health West. Pac. 2023, 30, 100611. [Google Scholar] [CrossRef] [PubMed]
- Nguyen, N.V.; Do, N.T.T.; Nguyen, C.T.K.; Tran, T.K.; Ho, P.D.; Nguyen, H.H.; Vu, H.T.L.; Wertheim, H.F.L.; Van Doorn, H.R.; Lewycka, S. Community-level consumption of antibiotics according to the AWaRe (Access, Watch, Reserve) classification in rural Vietnam. JAC Antimicrob. Resist. 2020, 2, dlaa048. [Google Scholar] [CrossRef] [PubMed]
- The VINARES consortium; Vu, T.V.D.; Choisy, M.; Do, T.T.N.; Nguyen, V.M.H.; Campbell, J.I.; Le, T.H.; Nguyen, V.T.; Wertheim, H.F.L.; Pham, N.T.; et al. Antimicrobial susceptibility testing results from 13 hospitals in Viet Nam: VINARES 2016-2017. Antimicrob. Resist. Infect. Control 2021, 10, 78. [Google Scholar] [CrossRef] [PubMed]
- Nguyen, T.T.P.; Do, T.X.; Nguyen, H.A.; Nguyen, C.T.T.; Meyer, J.C.; Godman, B.; Skosana, P.; Nguyen, B.T. A National Survey of Dispensing Practice and Customer Knowledge on Antibiotic Use in Vietnam and the Implications. Antibiotics 2022, 11, 1091. [Google Scholar] [CrossRef] [PubMed]
- Pham, G.N.; Dang, T.T.H.; Nguyen, T.-A.; Zawahir, S.; Le, H.T.T.; Negin, J.; Schneider, C.H.; Fox, G.J. Health system barriers to the implementation of the national action plan to combat antimicrobial resistance in Vietnam: A scoping review. Antimicrob. Resist. Infect. Control 2024, 13, 12. [Google Scholar] [CrossRef] [PubMed]
- Sulis, G.; Sayood, S.; Katukoori, S.; Bollam, N.; George, I.; Yaeger, L.H.; Chavez, M.A.; Tetteh, E.; Yarrabelli, S.; Pulcini, C.; et al. Exposure to World Health Organization’s AWaRe antibiotics and isolation of multidrug resistant bacteria: A systematic review and meta-analysis. Clin. Microbiol. Infect. 2022, 28, 1193–1202. [Google Scholar] [CrossRef] [PubMed]
- Kuitunen, I.; Jääskeläinen, J.; Korppi, M.; Renko, M. Antibiotic Treatment Duration for Community-Acquired Pneumonia in Outpatient Children in High-Income Countries—A Systematic Review and Meta-Analysis. Clin. Infect. Dis. 2022, 76, e1123–e1128. [Google Scholar] [CrossRef] [PubMed]
- Potpalle, D.; Gada, S.; Devaguru, A.; Behera, N.; Dinesh Eshwar, M. Comparison of Short-Term Versus Long-Term Antibiotic Therapy Among Severe Cases of Pneumonia: A Prospective Observational Study Among Children. Cureus 2023, 15, e35298. [Google Scholar] [CrossRef] [PubMed]
- Li, Q.; Zhou, Q.; Florez, I.D.; Mathew, J.L.; Shang, L.; Zhang, G.; Tian, X.; Fu, Z.; Liu, E.; Luo, Z.; et al. Short-Course vs Long-Course Antibiotic Therapy for Children With Nonsevere Community-Acquired Pneumonia: A Systematic Review and Meta-analysis. JAMA Pediatr. 2022, 176, 1199–1207. [Google Scholar] [CrossRef] [PubMed]
- Agarwal, G.; Awasthi, S.; Kabra, S.K.; Kaul, A.; Singhi, S.; Walter, S.D. Three day versus five day treatment with amoxicillin for non-severe pneumonia in young children: A multicentre randomised controlled trial. BMJ 2004, 328, 791. [Google Scholar] [CrossRef] [PubMed]
- The Pneumonia Etiology Research for Child Health (PERCH) Study Group. Causes of severe pneumonia requiring hospital admission in children without HIV infection from Africa and Asia: The PERCH multi-country case-control study. Lancet 2019, 394, 757–779. [Google Scholar] [CrossRef] [PubMed]
- Nguyen, S.T.T.; Tran, T.A.; Van Vo, G. Severe Pneumonia Caused by Respiratory Syncytial Virus and Adenovirus in Children from 2 to 24 Months at Children’s Hospital 1 in Ho Chi Minh City, Vietnam. Viruses 2024, 16, 410. [Google Scholar] [CrossRef] [PubMed]
- Nguyen, P.T.; Tran, H.T.; Fitzgerald, D.A.; Graham, S.M.; Marais, B.J. Antibiotic use in children hospitalised with pneumonia in Central Vietnam. Arch. Dis. Child. 2020, 105, 713–719. [Google Scholar] [CrossRef] [PubMed]
- Thị Kiều Anh, T.; Văn Tuấn, N. Study on the status of antibiotic use in the treatment of pneumonia in patients from 2 months to 5 years old at Nghe An obstetrics and pediatrics hospital. Vietnam. Med. J. 2021, 505, 254–257. [Google Scholar]
- Nguyen, D.B.T.; Nguyen, M.H.; Nguyen, H.A.; Phan, T.Q.; Nguyen, D.H. Research on Antibiotic Use Patterns in the Treatment of Community—Acquired Pneumonia in Children from 2 Months to 5 Years Old at the Department of Pediatrics, Quang Nam Central General Hospital. Cantho J. Med. Pharm. 2024, 74, 195–202. [Google Scholar]
- Thiện, N.T.; Huy, M.N.; Quang, N.N.; Thuận, N.H. Analysing of antibiotic use in the treatment of community-acquired pneumonia in children at Can Tho children’s hospital in 2024. Vietnam. Med. J. 2025, 3, 387–391. [Google Scholar]
- Ngocho, J.S.; Horumpende, P.G.; de Jonge, M.I.; Mmbaga, B.T. Inappropriate treatment of community-acquired pneumonia among children under five years of age in Tanzania. Int. J. Infect. Dis. 2020, 93, 56–61. [Google Scholar] [CrossRef] [PubMed]
- Pokhrel, B.; Koirala, T.; Gautam, D.; Kumar, A.; Camara, B.S.; Saw, S.; Daha, S.K.; Gurung, S.; Khulal, A.; Yadav, S.K.; et al. Antibiotic Use and Treatment Outcomes among Children with Community-Acquired Pneumonia Admitted to a Tertiary Care Public Hospital in Nepal. Trop. Med. Infect. Dis. 2021, 6, 55. [Google Scholar] [CrossRef] [PubMed]
- Le Thi, T.V.; Pham, E.C.; Dang-Nguyen, D.-T. Evaluation of children’s antibiotics use for outpatient pneumonia treatment in Vietnam. Braz. J. Infect. Dis. 2024, 28, 103839. [Google Scholar] [CrossRef] [PubMed]
- Larsson, M.; Nguyen, H.Q.; Olson, L.; Tran, T.K.; Nguyen, T.V.; Nguyen, C.T.K. Multi-drug resistance in Streptococcus pneumoniae among children in rural Vietnam more than doubled from 1999 to 2014. Acta Paediatr. 2021, 110, 1916–1923. [Google Scholar] [CrossRef] [PubMed]
- Dai, V.T.T.; Beissbarth, J.; Thanh, P.V.; Hoan, P.T.; Thuy, H.N.L.; Huu, T.N.; Bright, K.; Satzke, C.; Mulholland, E.K.; Temple, B.; et al. Hospital surveillance predicts community pneumococcal antibiotic resistance in Vietnam. J. Antimicrob. Chemother. 2020, 75, 2902–2906. [Google Scholar] [CrossRef] [PubMed]
- Tran-Quang, K.; Nguyen-Thi-Dieu, T.; Tran-Do, H.; Pham-Hung, V.; Nguyen-Vu, T.; Tran-Xuan, B.; Larsson, M.; Duong-Quy, S. Antibiotic resistance of Streptococcus pneumoniae in Vietnamese children with severe pneumonia: A cross-sectional study. Front. Public Health 2023, 11, 1110903. [Google Scholar] [CrossRef] [PubMed]
- Phi, D.L.; To, M.M.; Le, K.D.; Pham, T.D.; Vu, C.T.; Duong, K.L.; Dao, T.L.; Hoang, V.T. Commentary: Adenovirus and Mycoplasma pneumoniae co-infection as a risk factor for severe community-acquired pneumonia in children. Front. Pediatr. 2024, 12, 1464813. [Google Scholar] [CrossRef] [PubMed]
- Ding, G.; Zhang, X.; Vinturache, A.; van Rossum, A.M.C.; Yin, Y.; Zhang, Y. Challenges in the treatment of pediatric Mycoplasma pneumoniae pneumonia. Eur. J. Pediatr. 2024, 183, 3001–3011. [Google Scholar] [CrossRef] [PubMed]
- Nguyen, Y.T.B.; Tran, T.T.; Le, T.T.T.; Nguyen, H.T.T.; Nguyen, C.M.; Le, H.T.B.; Phan, T.T.N.; Vo, T.T.T.; Bui, H.T.N.; Mai, V.T.; et al. Community-acquired pneumonia-causing bacteria and antibiotic resistance rate among Vietnamese patients: A cross-sectional study. Medicine 2022, 101, e30458. [Google Scholar]
- Le, H.H.; Nguyen, A.V.; Vu, L.H.; Nguyen, V.T.H.; Pham, H.Q.; Le, H.V.; Nguyen, S.T.; Le, H.T.; Dinh, H.V.; Le, N.V.; et al. Antimicrobial Resistance Patterns of Common Gram-Negative Microorganisms Isolated from Patients with Lower Respiratory Tract Infections in a Teaching Hospital in Vietnam. Jpn. J. Infect. Dis. 2024, 77, 144–154. [Google Scholar] [CrossRef] [PubMed]
- Nguyen, D.T.; Huynh, S.T.; Nguyen, H.N. Short-Term Readmission Following Community-Acquired Pneumonia: A Cross-Sectional Study. Hosp. Pharm. 2022, 57, 712–720. [Google Scholar] [CrossRef] [PubMed]
- Tran, K.Q.; Nguyen, T.T.D.; Pham, V.H.; Pham, Q.M.; Tran, H.D. Pathogenic Role and Antibiotic Resistance of Methicillin-Resistant Staphylococcus aureus (MRSA) Strains Causing Severe Community-Acquired Pneumonia in Vietnamese Children. Adv. Respir. Med. 2023, 91, 135–145. [Google Scholar] [CrossRef] [PubMed]
- Vo-Pham-Minh, T.; Tran-Cong, D.; Phan-Viet, H.; Dinh-Chi, T.; Nguyen-Thi-Hong, T.; Cao-Thi-My, T.; Nguyen-Thi-Dieu, H.; Vo-Thai, D.; Nguyen-Thien, V.; Duong-Quy, S. Staphylococcus aureus Pneumonia in Can Tho, Vietnam: Clinical Characteristics, Antimicrobial Resistance Profile and Risk Factors of Mortality. Pulm. Ther. 2024, 10, 193–205. [Google Scholar] [CrossRef] [PubMed]
- Nathwani, D.; Varghese, D.; Stephens, J.; Ansari, W.; Martin, S.; Charbonneau, C. Value of hospital antimicrobial stewardship programs [ASPs]: A systematic review. Antimicrob. Resist. Infect. Control 2019, 8, 35. [Google Scholar] [CrossRef] [PubMed]
- Cox, J.A.; Vlieghe, E.; Mendelson, M.; Wertheim, H.; Ndegwa, L.; Villegas, M.V.; Gould, I.; Hara, G.L. Antibiotic stewardship in low- and middle-income countries: The same but different? Clin. Microbiol. Infect. 2017, 23, 812–818. [Google Scholar] [CrossRef] [PubMed]
- Saleem, Z.; Godman, B.; Cook, A.; Khan, M.A.; Campbell, S.M.; Seaton, R.A.; Siachalinga, L.; Haseeb, A.; Amir, A.; Kurdi, A.; et al. Ongoing Efforts to Improve Antimicrobial Utilization in Hospitals Among African Countries and Implications for the Future. Antibiotics 2022, 11, 1824. [Google Scholar] [CrossRef] [PubMed]
- Siachalinga, L.; Mufwambi, W.; Lee, I.H. Impact of antimicrobial stewardship interventions to improve antibiotic prescribing for hospital inpatients in Africa: A systematic review and meta-analysis. J. Hosp. Infect. 2022, 129, 124–143. [Google Scholar] [CrossRef] [PubMed]
- Akpan, M.R.; Isemin, N.U.; Udoh, A.E.; Ashiru-Oredope, D. Implementation of antimicrobial stewardship programmes in African countries: A systematic literature review. J. Glob. Antimicrob. Resist. 2020, 22, 317–324. [Google Scholar] [CrossRef] [PubMed]
- Sarang, B.; Tiwary, A.; Gadgil, A.; Roy, N. Implementing antimicrobial stewardship to reduce surgical site infections: Experience and challenges from two tertiary-care hospitals in Mumbai, India. J. Glob. Antimicrob. Resist. 2020, 20, 105–109. [Google Scholar] [CrossRef] [PubMed]
- Fésüs, A.; Baluku, P.; Sipos, É.; Somodi, S.; Berczi-Kun, E.; Lekli, I.; Bácskay, I.; Benkő, R.; Vaskó, A. The effect of the antibiotic stewardship program (ASP) on community-acquired pneumonia (CAP): A before-after study. Front. Pharmacol. 2024, 15, 1406960. [Google Scholar] [CrossRef] [PubMed]
- Hoa, N.Q.; Thi Lan, P.; Phuc, H.D.; Chuc, N.T.K.; Stalsby Lundborg, C. Antibiotic prescribing and dispensing for acute respiratory infections in children: Effectiveness of a multi-faceted intervention for health-care providers in Vietnam. Glob. Health Action 2017, 10, 1327638. [Google Scholar] [CrossRef] [PubMed]
- Huong, V.T.L.; Ngan, T.T.D.; Thao, H.P.; Tu, N.T.C.; Quan, T.A.; Nadjm, B.; Kesteman, T.; Van Kinh, N.; van Doorn, H.R. Improving antimicrobial use through antimicrobial stewardship in a lower-middle income setting: A mixed-methods study in a network of acute-care hospitals in Viet Nam. J. Glob. Antimicrob. Resist. 2021, 27, 212–221. [Google Scholar] [CrossRef] [PubMed]
- Niaz, Q.; Godman, B.; Massele, A.; Campbell, S.; Kurdi, A.; Kagoya, H.R.; Kibuule, D. Validity of World Health Organisation prescribing indicators in Namibia’s primary healthcare: Findings and implications. Int. J. Qual. Health Care 2019, 31, 338–345. [Google Scholar] [CrossRef] [PubMed]
- Campbell, S.M.; Meyer, J.; Godman, B. Why Compliance to National Prescribing Guidelines is Important Especially across Sub-Saharan Africa and Suggestions for the Future. Biomed. Pharm. Sci. 2021, 4, 1–7. [Google Scholar]
- Bakir Ekinci, P.; Kara, E.; Telli Dizman, G.; Metin, S.; Inkaya, A.C.; Demirkan, K.; Coplu, L.; Unal, S. Compliance with guideline recommendations in the management of patients with hospitalized community-acquired pneumonia. J. Investig. Med. 2024, 72, 349–358. [Google Scholar] [CrossRef] [PubMed]
- Shakeel, S.; Iffat, W.; Qamar, A.; Ghuman, F.; Yamin, R.; Ahmad, N.; Ishaq, S.M.; Gajdács, M.; Patel, I.; Jamshed, S. Pediatricians’ Compliance to the Clinical Management Guidelines for Community-Acquired Pneumonia in Infants and Young Children in Pakistan. Healthcare 2021, 9, 701. [Google Scholar] [CrossRef] [PubMed]
- Funiciello, E.; Lorenzetti, G.; Cook, A.; Goelen, J.; Moore, C.E.; Campbell, S.M.; Godman, B.; Tong, D.; Huttner, B.; Chuki, P.; et al. Identifying AWaRe indicators for appropriate antibiotic use: A narrative review. J. Antimicrob. Chemother. 2024, 79, 3063–3077. [Google Scholar] [CrossRef] [PubMed]
- Nguyen, P.T.; Nguyen, T.T.; Huynh, L.T.; Graham, S.M.; Marais, B.J. Clinical algorithm reduces antibiotic use among children presenting with respiratory symptoms to hospital in central Vietnam. Pneumonia 2023, 15, 11. [Google Scholar] [CrossRef] [PubMed]
- Mustafa, Z.U.; Khan, A.H.; Salman, M.; Harun, S.N.; Meyer, J.C.; Godman, B. Paediatricians’ knowledge, perceptions, preparedness and involvement towards paediatric antimicrobial stewardship in Pakistan: Findings and the implications. JAC Antimicrob. Resist. 2024, 6, dlae193. [Google Scholar] [CrossRef] [PubMed]
- Fadare, J.O.; Ogunleye, O.; Iliyasu, G.; Adeoti, A.; Schellack, N.; Engler, D.; Massele, A.; Godman, B. Status of antimicrobial stewardship programmes in Nigerian tertiary healthcare facilities: Findings and implications. J. Glob. Antimicrob. Resist. 2019, 17, 132–136. [Google Scholar] [CrossRef] [PubMed]
- Vu, H.T.L.; Pham, T.T.T.; Duong, Y.H.; Truong, Q.A.; Nguyen, T.T.C.; Trinh, L.X.; Nguyen, H.T.H.; Le, M.Q.; Vu, V.H.; Chau, D.M.; et al. Antibiotic prescribing practices of medical doctors in a resource-limited setting and the influence of individual perceptions and stewardship support: A survey in three tertiary hospitals in Vietnam. JAC Antimicrob. Resist. 2024, 6, dlae064. [Google Scholar] [CrossRef] [PubMed]
- Do, N.T.T.; Li, R.; Dinh, H.T.T.; Nguyen, H.T.L.; Dao, M.Q.; Nghiem, T.N.M.; Nadjm, B.; Luong, K.N.; Cao, T.H.; Le, D.T.K.; et al. Improving antibiotic prescribing for community-acquired pneumonia in a provincial hospital in Northern Vietnam. JAC Antimicrob. Resist. 2021, 3, dlab040. [Google Scholar] [CrossRef] [PubMed]
- Salih, K.E.M.; Bilal, J.A.; Alfadeel, M.A.; Hamid, Y.; Eldouch, W.; Elsammani, E.; Ibrahim, S.A.; Adam, I. Poor adherence to the World Health Organization guidelines of treatment of severe pneumonia in children at Khartoum, Sudan. BMC Res. Notes 2014, 7, 531. [Google Scholar] [CrossRef] [PubMed]
- Sefah, I.A.; Essah, D.O.; Kurdi, A.; Sneddon, J.; Alalbila, T.M.; Kordorwu, H.; Godman, B. Assessment of adherence to pneumonia guidelines and its determinants in an ambulatory care clinic in Ghana: Findings and implications for the future. JAC Antimicrob. Resist. 2021, 3, dlab080. [Google Scholar] [CrossRef] [PubMed]
- La Vecchia, A.; Teklie, B.G.; Mulu, D.A.; Toitole, K.K.; Montalbetti, F.; Agostoni, C.; Hessebo, T.T.; Tsegaye, A.; Pietravalle, A.; Manenti, F.; et al. Adherence to WHO guidelines on severe pneumonia management in children and its impact on outcome: An observational study at Jinka General Hospital in Ethiopia. Front. Public Health 2023, 11, 1189684. [Google Scholar] [CrossRef] [PubMed]
- Mutinda, C.M.; Onyango, F.E.; Maleche-Obimbo, E.; Kumar, R.; Wamalwa, D.; Were, F.; Osano, B.; Mburugu, P. Adherence to Pneumonia Guidelines for Children 2–59 Months at Garrisa Provincial General Hospital. East. Afr. Med. J. 2014, 91, 13–20. [Google Scholar] [PubMed]
- Nguyen, P.T.K.; Tran, H.T.; Fitzgerald, D.A.; Tran, T.S.; Graham, S.M.; Marais, B.J. Characterisation of children hospitalised with pneumonia in central Vietnam: A prospective study. Eur. Respir. J. 2019, 54, 1802256. [Google Scholar] [CrossRef] [PubMed]
- Ministry of Health. Guidelines for Diagnosis and Treatment of Some Common Diseases in Children in Vietnam. Issued together with Decision No. 3312/QD-BYT—7 August 2015. Available online: https://kcb.vn/van-ban/huong-dan-chan-doan-va-dieu-tri-mot-so-benh-thuong-gap-o-tre-em.html (accessed on 2 May 2025).
- Lui, G.; To, H.K.W.; Lee, N.; Chan, R.W.Y.; Li, T.; Wong, R.Y.K.; Hui, D.S.C.; Ip, M. Adherence to Treatment Guideline Improves Patient Outcomes in a Prospective Cohort of Adults Hospitalized for Community-Acquired Pneumonia. Open Forum Infect. Dis. 2020, 7, ofaa146. [Google Scholar] [CrossRef] [PubMed]
- Phuong, N.T.K.; Hoang, T.T.; Van, P.H.; Tu, L.; Graham, S.M.; Marais, B.J. Encouraging rational antibiotic use in childhood pneumonia: A focus on Vietnam and the Western Pacific Region. Pneumonia 2017, 9, 7. [Google Scholar] [CrossRef] [PubMed]
- Belay, E.T.; Hayelom, H.M.; Adugna, B.; Birhan, N.; Asmamaw, K. Treatment outcome of community acquired pneumonia among pediatric patients admitted to pediatrics wards at university of Gondar comprehensive and specialized hospital, northwest Ethiopia: A Retrospective cohort study. BMC Pediatr. 2024, 24, 801. [Google Scholar] [CrossRef] [PubMed]
- Tannous, R.; Haddad, R.N.; Torbey, P.H. Management of Community-Acquired Pneumonia in Pediatrics: Adherence to Clinical Guidelines. Front. Pediatr. 2020, 8, 302. [Google Scholar] [CrossRef] [PubMed]
- AT, L. Analysis of Antibiotic Usage in Patients with Community-Acquired Pneumonia at E Hospital. Bachelor’s Thesis, Hanoi University of Pharmacy, Hanoi, Vietnam, 2016. [Google Scholar]
- Kreitmeyr, K.; von Both, U.; Pecar, A.; Borde, J.P.; Mikolajczyk, R.; Huebner, J. Pediatric antibiotic stewardship: Successful interventions to reduce broad-spectrum antibiotic use on general pediatric wards. Infection 2017, 45, 493–504. [Google Scholar] [CrossRef] [PubMed]
- Bergh, D.v.D.; Messina, A.P.; Goff, D.A.; van Jaarsveld, A.; Coetzee, R.; de Wet, Y.; Bronkhorst, E.; Brink, A.; Mendelson, M.; A Richards, G.; et al. A pharmacist-led prospective antibiotic stewardship intervention improves compliance to community-acquired pneumonia guidelines in 39 public and private hospitals across South Africa. Int. J. Antimicrob. Agents 2020, 56, 106189. [Google Scholar] [CrossRef] [PubMed]
- Puzz, L.; Plauche, E.A.; Cretella, D.A.; Harrison, V.A.; Wingler, M.J.B. Evaluation of a Pediatric Community-Acquired Pneumonia Antimicrobial Stewardship Intervention at an Academic Medical Center. Antibiotics 2023, 12, 780. [Google Scholar] [CrossRef] [PubMed]
- Foolad, F.; Huang, A.M.; Nguyen, C.T.; Colyer, L.; Lim, M.; Grieger, J.; Li, J.; Revolinski, S.; Mack, M.; Gandhi, T.; et al. A multicentre stewardship initiative to decrease excessive duration of antibiotic therapy for the treatment of community-acquired pneumonia. J. Antimicrob. Chemother. 2018, 73, 1402–1407. [Google Scholar] [CrossRef] [PubMed]
- Rossin, S.; Barbieri, E.; Cantarutti, A.; Martinolli, F.; Giaquinto, C.; Da Dalt, L.; Doná, D.; Karunasagar, I. Multistep antimicrobial stewardship intervention on antibiotic prescriptions and treatment duration in children with pneumonia. PLoS ONE 2021, 16, e0257993. [Google Scholar] [CrossRef] [PubMed]
- Mustafa, Z.U.; Salman, M.; Khan, A.H.; Harun, S.N.; Meyer, J.C.; Godman, B. Antimicrobial Use Among Hospitalized Neonates and Children; Findings and Implications from a Comprehensive Point Prevalence Survey Among General Tertiary Hospitals in Pakistan. Infect. Drug Resist. 2024, 17, 5411–5428. [Google Scholar] [CrossRef] [PubMed]
- Zhang, J.-S.; Liu, G.; Zhang, W.-S.; Shi, H.-Y.; Lu, G.; Zhao, C.-A.; Li, C.-C.; Li, Y.-Q.; Shao, Y.-N.; Tian, D.-Y.; et al. Antibiotic usage in Chinese children: A point prevalence survey. World J. Pediatr. 2018, 14, 335–343. [Google Scholar] [CrossRef] [PubMed]
- Moore, D.P.; Chetty, T.; Pillay, A.; Karsas, M.; Cloete, J.; Balakrishna, Y.; Reddy, T.; Archary, M.; van Kwawegen, A.; Thomas, R.; et al. Antibiotic and antifungal use in paediatric departments at three academic hospitals in South Africa. IJID Reg. 2024, 10, 151–158. [Google Scholar] [CrossRef] [PubMed]
- Gasparetto, J.; Tuon, F.F.; Oliveira, D.d.S.; Zequinao, T.; Pipolo, G.R.; Ribeiro, G.V.; Benincá, P.D.; Cruz, J.A.W.; Moraes, T.P. Intravenous-to-oral antibiotic switch therapy: A cross-sectional study in critical care units. BMC Infect. Dis. 2019, 19, 650. [Google Scholar] [CrossRef] [PubMed]
- Dellsperger, S.; Kramer, S.; Stoller, M.; Burger, A.; Geissbühler, E.; Amsler, I.; Hirsig, A.; Weyer, L.; Hebeisen, U.; Aebi, P.; et al. Early Switch From Intravenous to Oral Antibiotics in Skin and Soft Tissue Infections: An Algorithm-Based Prospective Multicenter Pilot Trial. Open Forum Infect. Dis. 2022, 9, ofac197. [Google Scholar] [CrossRef] [PubMed]
- Nathwani, D.; Lawson, W.; Dryden, M.; Stephens, J.; Corman, S.; Solem, C.; Li, J.; Charbonneau, C.; Baillon-Plot, N.; Haider, S.; et al. Implementing criteria-based early switch/early discharge programmes: A European perspective. Clin. Microbiol. Infect. 2015, 21 (Suppl. 2), S47–S55. [Google Scholar] [CrossRef] [PubMed]
- Cyriac, J.M.; James, E. Switch over from intravenous to oral therapy: A concise overview. J. Pharmacol. Pharmacother. 2014, 5, 83–87. [Google Scholar] [CrossRef] [PubMed]
- Saleem, Z.; Moore, C.E.; Kalungia, A.C.; Schellack, N.; Ogunleye, O.; Chigome, A.; Chowdhury, K.; Kitutu, F.E.; Massele, A.; Ramdas, N.; et al. Status and implications of the knowledge, attitudes and practices towards AWaRe antibiotic use, resistance and stewardship among low- and middle-income countries. JAC-Antimicrob. Resist. 2025, 7, dlaf033. [Google Scholar] [CrossRef] [PubMed]
- Miljković, N.; Polidori, P.; Kohl, S. Managing antibiotic shortages: Lessons from EAHP and ECDC surveys. Eur. J. Hosp. Pharm. 2022, 29, 90–94. [Google Scholar] [CrossRef] [PubMed]
- Pandey, A.K.; Cohn, J.; Nampoothiri, V.; Gadde, U.; Ghataure, A.; Kakkar, A.K.; Yogendra, K.G.; Malhotra, S.; Mbamalu, O.; Mendelson, M.; et al. A systematic review of antibiotic drug shortages and the strategies employed for managing these shortages. Clin. Microbiol. Infect. 2025, 31, 345–353. [Google Scholar] [CrossRef] [PubMed]
- Chigome, A.K.; Matlala, M.; Godman, B.; Meyer, J.C. Availability and Use of Therapeutic Interchange Policies in Managing Antimicrobial Shortages among South African Public Sector Hospitals; Findings and Implications. Antibiotics 2019, 9, 4. [Google Scholar] [CrossRef] [PubMed]
- Falco, M.F.; Meyer, J.C.; Putter, S.J.; Underwood, R.S.; Nabayiga, H.; Opanga, S.; Miljković, N.; Nyathi, E.; Godman, B. Perceptions of and Practical Experience with the National Surveillance Centre in Managing Medicines Availability Amongst Users within Public Healthcare Facilities in South Africa: Findings and Implications. Healthcare 2023, 11, 1838. [Google Scholar] [CrossRef] [PubMed]
- Chowdhury, K.; Haque, M.; Nusrat, N.; Adnan, N.; Islam, S.; Lutfor, A.B.; Begum, D.; Rabbany, A.; Karim, E.; Malek, A.; et al. Management of Children Admitted to Hospitals across Bangladesh with Suspected or Confirmed COVID-19 and the Implications for the Future: A Nationwide Cross-Sectional Study. Antibiotics 2022, 11, 105. [Google Scholar] [CrossRef] [PubMed]
- Kumar, S.; Haque, M.; Shetty, A.; Choudhary, S.; Bhatt, R.; Sinha, V.; Manohar, B.; Chowdhury, K.; Nusrat, N.; Jahan, N.; et al. Characteristics and Management of Children With Suspected COVID-19 Admitted to Hospitals in India: Implications for Future Care. Cureus 2022, 14, e27230. [Google Scholar] [CrossRef] [PubMed]
- van der Sandt, N.; Schellack, N.; Mabope, L.A.; Mawela, M.P.B.; Kruger, D.; Godman, B. Surgical Antimicrobial Prophylaxis Among Pediatric Patients in South Africa Comparing Two Healthcare Settings. Pediatr. Infect. Dis. J. 2019, 38, 122–126. [Google Scholar] [CrossRef] [PubMed]
- Guma, S.P.; Godman, B.; Campbell, S.M.; Mahomed, O. Determinants of the Empiric Use of Antibiotics by General practitioners in South Africa: Observational, Analytic, Cross-Sectional Study. Antibiotics 2022, 11, 1423. [Google Scholar] [CrossRef] [PubMed]
- Etando, A.; Amu, A.A.; Haque, M.; Schellack, N.; Kurdi, A.; Alrasheedy, A.A.; Timoney, A.; Mwita, J.C.; Rwegerera, G.M.; Patrick, O.; et al. Challenges and Innovations Brought about by the COVID-19 Pandemic Regarding Medical and Pharmacy Education Especially in Africa and Implications for the Future. Healthcare 2021, 9, 1722. [Google Scholar] [CrossRef] [PubMed]
- Godman, B.; Egwuenu, A.; Wesangula, E.; Schellack, N.; Kalungia, A.C.; Tiroyakgosi, C.; Kgatlwane, J.; Mwita, J.C.; Patrick, O.; Niba, L.L.; et al. Tackling antimicrobial resistance across sub-Saharan Africa: Current challenges and implications for the future. Expert Opin. Drug Saf. 2022, 21, 1089–1111. [Google Scholar] [CrossRef] [PubMed]
- Skosana, P.; Schellack, N.; Godman, B.; Kurdi, A.; Bennie, M.; Kruger, D.; Meyer, J. A national, multicentre, web-based point prevalence survey of antimicrobial use and quality indices among hospitalised paediatric patients across South Africa. J. Glob. Antimicrob. Resist. 2022, 29, 542–550. [Google Scholar] [CrossRef] [PubMed]
- Bui, T. Analysis of Antibiotic Usage in the Treatment of Community-Acquired Pneumonia at the Pediatrics Department of Bach Mai Hospital in 2018. Specialist Pharmacist Level I Thesis, Hanoi University of Pharmacy, Hanoi, Vietnam, 2019. [Google Scholar]
- Ministry of Health. Guidelines for the Use of Antibiotics. Issued with Decision No. 708/QD-BYT, Classified: 3 types P/SP/VSP; Ministry of Health: Hanoi, Vietnam, 2015. [Google Scholar]
- Van Tuong, P.; Xiem, C.H.; Anh, N.C.; Quang, L.N. Analysis of antibiotic use in the treatment of community-acquired pneumonia at the National Children’s Hospital. In Proceedings of the 6th Hanoi Hospital Pharmaceutical Science Conference, Hanoi, Vietnam, 6–7 December 2018. [Google Scholar]
- Tran, T. Analysis of Antibiotic Usage in the Treatment of Community-Acquired Pneumonia in Children Aged 2 Months to 5 Years at the Pediatric Department of Phu Tho Provincial General Hospital in the First Half of 2019. Specialist Pharmacist Level I Thesis, Hanoi University of Pharmacy, Hanoi, Vietnam, 2020. [Google Scholar]
Characteristics | n | % | |
---|---|---|---|
Age (months) | 27.94 ± 12.99 | ||
Gender (n = 108) | Male (n,%) | 55 | 50.9 |
Female (n,%) | 53 | 49.1 | |
Medical history—antibiotic use | |||
Antibiotics use pre-admission | Yes | 45 | 41.7 |
No | 55 | 50.9 | |
N/A | 8 | 7.4 | |
Clinical state on admission | |||
Severity | Non-severe pneumonia (n,%) | 89 | 82.4 |
Severe pneumonia (n,%) | 19 | 17.6 | |
Comorbidity | Yes (n,%) | 43 | 39.8 |
No (n,%) | 65 | 60.2 | |
Treatment duration and effectiveness | |||
Antibiotic treatment duration (days—Median) | 6.00 (5.25–7.00) | ||
Hospitalization duration (days—Median) | 7.00 (6.00–8.00) | ||
Outcome | Recover | 63 | 58.3 |
Reduced symptoms | 45 | 41.7 |
Initial Antibiotic Regimen | Non-Severe Pneumonia | Severe Pneumonia | Total | |||
---|---|---|---|---|---|---|
n | % | n | % | n | % | |
Monotherapy (including combinations) | 67 | 75.3 | 13 | 68.4 | 80 | 74.1 |
Penicillin/β-lactamase | ||||||
Amoxicillin/Sulbactam (IV) | 5 | 5.6 | 1 | 5.3 | 6 | 5.6 |
Amoxicillin/Clavulanic (IV) | 1 | 1.1 | 0 | 0.00 | 1 | 0.9 |
Ampicillin/Sulbactam (IV) | 0 | 0.00 | 1 | 5.3 | 1 | 0.9 |
Third-generation cephalosporin/β-lactamase combination | ||||||
Cefoperazone/Sulbactam (IV) | 34 | 38.2 | 7 | 36.8 | 41 | 38.0 |
Third-generation cephalosporins | ||||||
Cefotaxime (IV) | 18 | 20.2 | 3 | 15.8 | 21 | 19.4 |
Cefotiam (IV) | 3 | 3.4 | 1 | 5.3 | 4 | 3.7 |
Ceftizoxime (IV) | 5 | 5.6 | 0 | 0.00 | 5 | 4.6 |
Macrolides | 1 | 0.9 | ||||
Clarithromycin (O) | 1 | 1.1 | 0 | 0.00 | 1 | 0.9 |
Combination regimens | 22 | 24.7 | 6 | 31.6 | 28 | 25.9 |
Third-generation cephalosporins/inhibitor β-lactamase + Aminoglycoside | ||||||
Cefoperazone/Sulbactam (IV) + Amikacin (IV) | 5 | 5.6 | 2 | 10.5 | 7 | 6.5 |
Third-generation cephalosporins/inhibitor β-lactamase + Macrolides | ||||||
Cefoperazone/Sulbactam (IV) + Azithromycin (O) | 1 | 1.1 | 1 | 5.3 | 2 | 1.9 |
Cefoperazone/Sulbactam (IV) + Clarithromycin (O) | 1 | 1.1 | 0 | 0.00 | 1 | 0.9 |
Third-generation cephalosporins + Aminoglycosides | ||||||
Cefotaxims (IV) + Gentamicin (IV) | 3 | 3.4 | 2 | 10.5 | 5 | 4.6 |
Cefotaxime (IV) + Amikacin (IV) | 1 | 1.1 | 0 | 0.00 | 1 | 0.9 |
Ceftizoxime (IV) + Amikacin (IV) | 3 | 3.4 | 0 | 0.00 | 3 | 2.8 |
Cefotiam (IV) + Amikacin (IV) | 1 | 1.1 | 0 | 0.00 | 1 | 0.9 |
Third-generation cephalosporins + Macrolides | ||||||
Cefotaxime (IV) + Azithromycin (O) | 2 | 2.3 | 0 | 0.00 | 2 | 1.9 |
Cefotiam (IV) + Azithromycin (O) | 1 | 1.1 | 0 | 0.00 | 1 | 0.9 |
Cefotaxime (IV) + Clarithromycin (O) | 2 | 2.3 | 0 | 0.00 | 2 | 1.9 |
Third-generation cephalosporins/inhibitor β-lactamase + Aminoglycosides + Macrolides | ||||||
Cefoperazone/Sulbactam (IV) + Amikacin (IV) + Clarithromycin (O) | 0 | 0.00 | 1 | 5.3 | 1 | 0.9 |
Third-generation cephalosporins + Aminoglycosides + Macrolides | ||||||
Ceftizoxime (IV) + Amikacin (IV) + Clarithromycin(O) | 1 | 1.1 | 0 | 0.00 | 1 | 0.9 |
Cefotiam (IV) + Gentamicin (IV) + Azithromycin(O) | 1 | 1.1 | 0 | 0.00 | 1 | 0.9 |
Total | 89 | 100.00 | 19 | 100.00 | 108 | 100.00 |
Initial Antibiotics | Classification * | Route of Drug Administration | Daily Dosage | |||||
---|---|---|---|---|---|---|---|---|
Lower | Appropriate | Higher | ||||||
n | % | n | % | n | % | |||
Amikacin | A | IV | 1 | 7.1 | 12 | 85.7 | 1 | 7.1 |
Amoxicillin/Sulbactam | N/A | IV | 1 | 16.7 | 5 | 83.3 | 0 | 0.0 |
Amoxicillin/Clavulanic | A | IV | 0 | 0.0 | 1 | 100.0 | 0 | 0.0 |
Ampicillin/Sulbactam | A | IV | 0 | 0.0 | 1 | 100.0 | 0 | 0.0 |
Azithromycin | W | O | 3 | 60.0 | 0 | 0.0 | 2 | 40.0 |
Cefoperazone/Sulbactam | W | IV | 0 | 0.0 | 2 | 3.9 | 49 | 96.1 |
Cefotaxime | W | IV | 12 | 38.7 | 19 | 61.0 | 0 | 0.0 |
Cefotiam | W | IV | 1 | 16.7 | 5 | 83.33 | 0 | 0.0 |
Ceftizoxime | W | IV | 4 | 44.4 | 5 | 55.6 | 0 | 0.0 |
Clarithromycin | W | O | 0 | 0.0 | 3 | 60.0 | 2 | 40.0 |
Gentamicin | A | IV | 1 | 16.7 | 4 | 66.7 | 1 | 16.7 |
Total | 23 | 17.0 | 57 | 42.2 | 55 | 40.7 |
Microbiological Test Characteristics | Variable | (n) | (%) |
---|---|---|---|
Microbiological test (n = 108) | Yes | 100 | 92.6 |
No | 8 | 7.4 | |
Time of sampling test (n = 100) | Date of entry to hospital After entry hospital day | 98 2 | 98.0 2.0 |
Tissue for testing (n = 160) | Throat Blood Other | 97 34 29 | 60.6 21.6 18.1 |
Result (n = 160) | Positive | 47 | 29.4 |
Negative | 113 | 70.6 | |
Results of testing (n = 47) | Bacteria | 40 | 85.1 |
Virus | 7 | 14.9 | |
Bacterial strains identified (n = 40) | H.influenzae | 25 | 53.2 |
M.catarrhalis | 12 | 25.5 | |
S.aureus | 2 | 4.3 | |
S.pneumoniae | 1 | 2.1 | |
M.pneumoniae | 0 | 0.0 | |
P.aeruginosa | 0 | 0.0 | |
Time received microbiological test (n = 47) | <3 days | 20 | 42.6 |
3 days | 16 | 34.0 | |
4 days | 10 | 21.3 | |
5 days | 1 | 2.1 |
Barriers to Adherence to Recommended Initial Antibiotic Selection | Comment Transcripts | |
---|---|---|
Internal barriers | Doctors′ experience and prescription habits (5/5) | “The time of diagnosing pneumonia often does not align with the patient′s hospital admission, as many patients have already undergone prior treatment. This makes it challenging to apply standard guidelines accurately, re-sulting in a naturally low compliance rate.” [Dr1]; “Like here is a central hospital, patients have used many antibiotics so of course there are no initial options like simple amoxicillin.” [Dr2]. |
Doctor′s treatment perspective: “Recommendations are just recom-mendation”. (2/5) | “Treatment regimens are often theoretical and meant for reference, as there are differences between reality and actual patient populations. Clinical practice requires flexibility, so directly applying theoretical guidelines of-ten leads to low compatibility” [Dr4]. | |
External barriers | Inadequate antibiotics supply (5/5) | “A major challenge is the inconsistent availability of medicines, with shortages and unexpected stockouts forcing patients to switch up to three types of medicine within a week. Often, only limited antibiotic options are available, such as third-generation cephalosporins” [Dr3]. “The only antibiotic covered by health insurance is aug-mentin, but the quantity is very limited. When the patient is hospitalized, there is a group of third-generation ceph-alosporin antibiotics, there is almost no second choice” [Dr5]. |
Outdated guidelines (3/5) | “Regular updates to guidelines would greatly assist doc-tors, but in Vietnam, updates are infrequent, with some regimens remaining unchanged for years. Pediatric guidebooks are only published every few years, causing delays in adopting global advancements. Frequent up-dates would improve compliance among doctors” [Dr4]. | |
Impractical guidelines (2/5) | “In clinical practice, there are discrepancies from the guidelines because patients often have already used multiple medications before hospital admission” [Dr4]. | |
Inappropriate patient approaches (1/5) | “Classifying patients based on pneumonia severity is typically used in community and lower-level hospitals. In contrast, higher-level hospitals focus more on identifying the underlying causes to choose antibiotics, rather than relying solely on severity, even when the patient exhibits symptoms of respiratory failure from communi-ty-acquired pneumonia” [Dr1]. |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Nguyen, T.T.P.; Vu, H.T.T.; Hoang, A.M.; Ho, A.M.; Sefah, I.A.; Godman, B.; Meyer, J.C. Barriers to Compliance with National Guidelines Among Children Hospitalized with Community-Acquired Pneumonia in Vietnam and the Implications. Antibiotics 2025, 14, 709. https://doi.org/10.3390/antibiotics14070709
Nguyen TTP, Vu HTT, Hoang AM, Ho AM, Sefah IA, Godman B, Meyer JC. Barriers to Compliance with National Guidelines Among Children Hospitalized with Community-Acquired Pneumonia in Vietnam and the Implications. Antibiotics. 2025; 14(7):709. https://doi.org/10.3390/antibiotics14070709
Chicago/Turabian StyleNguyen, Thuy Thi Phuong, Huong Thi Thu Vu, Anh Minh Hoang, An Minh Ho, Israel Abebrese Sefah, Brian Godman, and Johanna C. Meyer. 2025. "Barriers to Compliance with National Guidelines Among Children Hospitalized with Community-Acquired Pneumonia in Vietnam and the Implications" Antibiotics 14, no. 7: 709. https://doi.org/10.3390/antibiotics14070709
APA StyleNguyen, T. T. P., Vu, H. T. T., Hoang, A. M., Ho, A. M., Sefah, I. A., Godman, B., & Meyer, J. C. (2025). Barriers to Compliance with National Guidelines Among Children Hospitalized with Community-Acquired Pneumonia in Vietnam and the Implications. Antibiotics, 14(7), 709. https://doi.org/10.3390/antibiotics14070709